[{"address1": "1210-1220 Washington St.", "address2": "Suite 210", "city": "Newton", "state": "MA", "zip": "02465", "country": "United States", "phone": "617 344 4190", "website": "https://acumenpharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel J. O'Connell M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1047590, "exercisedValue": 0, "unexercisedValue": 1034567}, {"maxAge": 1, "name": "Dr. James  Doherty Ph.D.", "age": 56, "title": "President & Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 730785, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Zuga", "title": "CFO & Chief Business Officer", "fiscalYear": 2024, "totalPay": 703157, "exercisedValue": 0, "unexercisedValue": 254161}, {"maxAge": 1, "name": "Dr. Grant A. Krafft Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "totalPay": 42000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caleb E. Finch Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Klein Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Russell  Barton M.S.", "age": 65, "title": "Chief Operating Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 223680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Carranza", "title": "Vice President, Finance & Accounting and Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alex  Braun M.B.A.", "title": "VP & Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derek M. Meisner Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 752945, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.9963, "open": 0.981, "dayLow": 0.9586, "dayHigh": 1.0, "regularMarketPreviousClose": 0.9963, "regularMarketOpen": 0.981, "regularMarketDayLow": 0.9586, "regularMarketDayHigh": 1.0, "payoutRatio": 0.0, "beta": 0.091, "forwardPE": -0.6446405, "volume": 67154, "regularMarketVolume": 67154, "averageVolume": 228213, "averageVolume10days": 173720, "averageDailyVolume10Day": 173720, "bid": 0.6963, "ask": 1.25, "bidSize": 2, "askSize": 2, "marketCap": 59743544, "fiftyTwoWeekLow": 0.855, "fiftyTwoWeekHigh": 3.92, "fiftyDayAverage": 1.12908, "twoHundredDayAverage": 2.019045, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -81505696, "profitMargins": 0.0, "floatShares": 32929531, "sharesOutstanding": 60573400, "sharesShort": 1757576, "sharesShortPriorMonth": 1775675, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.029000001, "heldPercentInsiders": 0.11414, "heldPercentInstitutions": 0.75851, "shortRatio": 7.12, "shortPercentOfFloat": 0.039100002, "impliedSharesOutstanding": 62996400, "bookValue": 3.026, "priceToBook": 0.32594183, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -102329000, "trailingEps": -1.71, "forwardEps": -1.53, "enterpriseToEbitda": 0.715, "52WeekChange": -0.7210084, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 0.9863, "targetHighPrice": 11.0, "targetLowPrice": 4.0, "targetMeanPrice": 9.2, "targetMedianPrice": 10.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 171556992, "totalCashPerShare": 2.832, "ebitda": -113954000, "totalDebt": 29702000, "quickRatio": 6.237, "currentRatio": 6.459, "debtToEquity": 16.336, "returnOnAssets": -0.25955, "returnOnEquity": -0.45602, "grossProfits": -93798000, "freeCashflow": -52293124, "operatingCashflow": -86215000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ABOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Acumen Pharmaceuticals, Inc.", "longName": "Acumen Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1625146200000, "regularMarketChange": -0.00999999, "regularMarketDayRange": "0.9586 - 1.0", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 228213, "fiftyTwoWeekLowChange": 0.13129997, "fiftyTwoWeekLowChangePercent": 0.15356721, "fiftyTwoWeekRange": "0.855 - 3.92", "fiftyTwoWeekHighChange": -2.9337, "fiftyTwoWeekHighChangePercent": -0.7483929, "fiftyTwoWeekChangePercent": -72.100845, "corporateActions": [], "regularMarketTime": 1746725393, "marketState": "REGULAR", "earningsTimestamp": 1747139400, "earningsTimestampStart": 1747139400, "earningsTimestampEnd": 1747139400, "earningsCallTimestampStart": 1747137600, "earningsCallTimestampEnd": 1747137600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.71, "epsForward": -1.53, "epsCurrentYear": -2.31978, "priceEpsCurrentYear": -0.42516962, "fiftyDayAverageChange": -0.14278007, "fiftyDayAverageChangePercent": -0.12645699, "twoHundredDayAverageChange": -1.0327451, "twoHundredDayAverageChangePercent": -0.5115017, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-01", "cryptoTradeable": false, "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "regularMarketChangePercent": -0.99078476, "regularMarketPrice": 0.9863, "exchange": "NMS", "messageBoardId": "finmb_8539521", "market": "us_market", "displayName": "Acumen Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]